StreetInsider.com News Articles

Form 8-K Xtant Medical Holdings, For: Mar 02

Mon, 02 Mar 2026 08:16:00 -0500

si-local-file:///var/storage/secattach/20260302/26087475.html

Form 8-K Xtant Medical Holdings, For: Mar 02

Mon, 02 Mar 2026 08:16:00 -0500

si-local-file:///var/storage/secattach/20260302/26087475.html

Xtant Medical receives $10.7 million from Companion Spine deal completion

Mon, 02 Mar 2026 08:02:30 -0500

Xtant Medical Holdings Inc. (NYSE American: XTNT) received $10.7 million from Companion Spine, finalizing transactions for the sale of its Coflex assets and Paradigm OUS businesses, the company announced March 2.

The payment brings the total aggregate purchase price for both divestitures to $21.4 million. Companion Spine initially purchased the assets in December 2025.

Of the $10.7 million received, $8.2 million satisfied an unsecured promissory note issued to Xtant by Companion Spine, plus accrued interest. An additional $2.2 million related to working capital and other purchase price adjustments.

"We are very pleased to finalize these transactions with Companion Spine, which place these assets

Xtant Medical Finalizes Companion Spine Transactions

Mon, 02 Mar 2026 08:00:00 -0500

Xtant received $10.7 million in satisfaction of unsecured promissory note issued to Xtant by Companion Spine plus related working capital adjustments

BELGRADE, Mont., March 2, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced that it has received $10.7 million from Companion Spine related to Companion Spine's purchase of Xtant's Coflex® assets and Paradigm OUS businesses in December 2025, bringing the total aggregate purchase price for the two divestitures to $21.4 million.

Xtant Medical Finalizes Companion Spine Transactions

Mon, 02 Mar 2026 08:00:00 -0500

Xtant received $10.7 million in satisfaction of unsecured promissory note issued to Xtant by Companion Spine plus related working capital adjustments

Xtant Medical Finalizes Companion Spine Transactions

Mon, 02 Mar 2026 08:00:00 -0500

Xtant received $10.7 million in satisfaction of unsecured promissory note issued to Xtant by Companion Spine plus related working capital adjustments

Xtant Medical Finalizes Companion Spine Transactions

Mon, 02 Mar 2026 08:00:00 -0500

Xtant received $10.7 million in satisfaction of unsecured promissory note issued to Xtant by Companion Spine plus related working capital adjustments

Xtant Medical to Participate in the Canaccord Genuity 2026 Musculoskeletal Conference

Wed, 25 Feb 2026 08:00:00 -0500

BELGRADE, Mont., Feb. 25, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and wound care disorders, today announced that Sean Browne, CEO, Scott Neils, CFO, and Mark Schallenberger, COO, will be participating in the Canaccord Genuity 2026 Musculoskeletal Conference, which is being held March 2, 2026, in New Orleans and virtually.

Xtant Medical to Participate in the Canaccord Genuity 2026 Musculoskeletal Conference

Wed, 25 Feb 2026 08:00:00 -0500

Xtant Medical to Participate in the Canaccord Genuity 2026 Musculoskeletal Conference

Wed, 25 Feb 2026 08:00:00 -0500

Xtant Medical to Participate in the Canaccord Genuity 2026 Musculoskeletal Conference

Wed, 25 Feb 2026 08:00:00 -0500

Form 4 Xtant Medical Holdings, For: Feb 15 Filed by: Schallenberger Mark A.

Wed, 18 Feb 2026 16:37:00 -0500

si-local-file:///var/storage/secattach/20260218/26022802.html

Form 4 Xtant Medical Holdings, For: Feb 15 Filed by: Schallenberger Mark A.

Wed, 18 Feb 2026 16:37:00 -0500

si-local-file:///var/storage/secattach/20260218/26022802.html

Form SCHEDULE 13G/A Xtant Medical Holdings, Filed by: LYTTON LAURENCE W

Tue, 17 Feb 2026 12:58:00 -0500

si-local-file:///var/storage/secattach/20260217/26010400.html

Form SCHEDULE 13G/A Xtant Medical Holdings, Filed by: LYTTON LAURENCE W

Tue, 17 Feb 2026 12:58:00 -0500

si-local-file:///var/storage/secattach/20260217/26010400.html

Form 4 Xtant Medical Holdings, For: Jan 15 Filed by: Neils Scott C

Fri, 16 Jan 2026 17:00:00 -0500

si-local-file:///var/storage/secattach/20260116/25861063.html

Form 4 Xtant Medical Holdings, For: Jan 15 Filed by: Neils Scott C

Fri, 16 Jan 2026 17:00:00 -0500

si-local-file:///var/storage/secattach/20260116/25861063.html

Form 8-K Xtant Medical Holdings, For: Jan 15

Fri, 16 Jan 2026 16:16:00 -0500

si-local-file:///var/storage/secattach/20260116/25860442.html

Form 8-K Xtant Medical Holdings, For: Jan 15

Fri, 16 Jan 2026 16:16:00 -0500

si-local-file:///var/storage/secattach/20260116/25860442.html

Xtant Medical launches nanOss Strata synthetic bone graft product

Thu, 11 Dec 2025 08:01:27 -0500

Xtant Medical Holdings Inc. (NYSE American: XTNT) announced the commercial launch of nanOss Strata, a synthetic bone graft product, according to a company statement.

The product is manufactured from hydroxycarbonapatite, which the company states has higher solubility than traditional hydroxyapatite commonly used in synthetic materials. Xtant Medical said the nanocrystalline structure is designed to mimic human bone structure and increase surface area.

nanOss Strata is available in compression-resistant preformed strips and prehydrated moldable grafts. The company said both options are sterile, moldable, and absorb blood and other biologic fluids.

"By building on the clinical success of our nanOss products, Strata further demonstrates our

Xtant Medical Announces Commercial Launch of its Next-Generation nanOss Strata™ Synthetic Bone Graft

Thu, 11 Dec 2025 08:00:00 -0500

nanOss Strata™ is designed to more closely mimic the structure of human bone, increase the graft's surface area, improve osteoconductivity and enhance the stimulation of cellular activity

BELGRADE, Mont., Dec. 11, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced the commercial launch of its next-generation innovative synthetic bone graft in the nanOss line, Strata™.

Xtant Medical Announces Commercial Launch of its Next-Generation nanOss Strata™ Synthetic Bone Graft

Thu, 11 Dec 2025 08:00:00 -0500

nanOss Strata™ is designed to more closely mimic the structure of human bone, increase the graft's surface area, improve osteoconductivity and enhance the stimulation of cellular activity

Xtant Medical Announces Commercial Launch of its Next-Generation nanOss Strata™ Synthetic Bone Graft

Thu, 11 Dec 2025 08:00:00 -0500

nanOss Strata™ is designed to more closely mimic the structure of human bone, increase the graft's surface area, improve osteoconductivity and enhance the stimulation of cellular activity

Xtant Medical Announces Commercial Launch of its Next-Generation nanOss Strata™ Synthetic Bone Graft

Thu, 11 Dec 2025 08:00:00 -0500

nanOss Strata™ is designed to more closely mimic the structure of human bone, increase the graft's surface area, improve osteoconductivity and enhance the stimulation of cellular activity

Form 8-K Xtant Medical Holdings, For: Dec 01

Wed, 03 Dec 2025 16:06:00 -0500

si-local-file:///var/storage/secattach/20251203/25695429.html